People who undergo Roux-en-Y gastric bypass following sleeve gastrectomy achieve significantly greater long-term weight loss compared to those who are treated with GLP-1 receptor agonists, according to new findings from a multicentre retrospective study.

mylife CamAPS FX app launches on iOS in the UK, empowering easier diabetes management

A new ‘next-generation’ continuous glucose monitor (CGM) by Chinese manufacturing giant Yuwell is now available in the UK.

Children with a body mass index (BMI) of over 50 are among thousands referred to specialist NHS clinics in England for treatment of severe obesity, with new research revealing a striking link between excess weight, deprivation and complex health needs.

Weight-loss surgeries for adolescents increased 15 per cent in the U.S. between 2021 and 2023, even as the Food and Drug Administration (FDA) approved effective new weight-loss medications for this age group, a study led by UT Southwestern Medical Center researchers shows. Their findings, published in The Journal of Pediatrics, shed light on how severe obesity is being treated in teenagers, the fastest-growing age group with this condition.

The National Institute for Health and Care Excellence (NICE) has released a new guideline – NG246 Overweight and obesity: clinical assessment and management.

New findings presented at the European Congress on Obesity (ECO 2025) reveal important gender-based differences in how fat is broken down for energy, offering new insights into metabolic health and the risk of type 2 diabetes.

New research presented at this year’s European Congress on Obesity (ECO 2025), suggests that weight loss programmes that set specific percentage weight loss goals are often falling short — and may not always reflect the most meaningful health outcomes for people living with obesity.

A new study unveiled at this year’s European Congress on Obesity in Malaga revealed that tirzepatide delivers significantly greater weight loss than semaglutide in people living with obesity, but without diabetes.

New draft quality standard aims to boost early intervention and consistent care for adults living with long-term health conditions.

A new analysis from the landmark SUMMIT trial has revealed that tirzepatide, a drug already approved for weight loss and type 2 diabetes, offers significant benefits for people living with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction (HFpEF).

The number of teenagers in England who are living with overweight or obese has risen by 50 per cent since 2008, according to new research. Experts say the sharp increase is largely driven by the consumption of ultra-processed foods and increasingly sedentary lifestyles shaped by excessive screen time.

A new international analysis has revealed important insights into the two-way relationship between obesity and obstructive sleep apnea (OSA), reinforcing the need for a broader approach to identifying and managing the condition.

A new phase 2 trial has shown that higher doses of semaglutide — up to 16 mg weekly — may deliver greater weight loss benefits in people with living with type 2 diabetes and overweight or obesity, though with increased side effects.

Novo Nordisk has submitted a pill version of its obesity drug for approval by the US Food and Drug Administration, the company has confirmed.

All schools in Spain are now legally required to serve fruit and vegetables daily and include fish in lunches at least once a week, under new legislation designed to combat childhood obesity.

New UK research being presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) reveals that women are significantly more aware of obesity medications known as GLP-1/GIP receptor agonists than men. These medications include semaglutide and tirzepatide.

A US report has highlighted a worrying increase in obesity-related cancer deaths and warns that more cases may be diagnosed at a later stage due to disruptions caused by the COVID-19 pandemic.

The United States could see one of the sharpest drops in obesity rates globally, thanks to the growing use of weight loss drugs such as Ozempic and Wegovy, according to a new report.

Medications used to treat obesity and type 2 diabetes — particularly semaglutides such as Ozempic and Wegovy — may reduce the risk of dementia, according to new research.